Next-Gen Obesity Peptides
2 articles in this topic.
Next-Gen Obesity Peptides
Beyond Triple Agonists: Quadruple Targets?
After retatrutide's 28.7% weight loss, researchers are exploring quadruple receptor agonists targeting GLP-1, GIP, glucagon, and additional pathways like IGF-1.
13 min read|Mar 21, 2026
Next-Gen Obesity Peptides
Danuglipron: Pfizer's Oral GLP-1 That Didn't Make It
Danuglipron showed up to 13% weight loss in Phase 2b but was discontinued in 2025 after liver injury signal and 50%+ dropout rates. Full clinical data review.
13 min read|Mar 21, 2026